Max Masucci
Stock Analyst at TD Cowen
(0.23)
# 4,031
Out of 4,670 analysts
28
Total ratings
16%
Success rate
-31.44%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $57.07 | +26.16% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $26.01 | -3.88% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $32.65 | +62.33% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $78.97 | +20.30% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $11.75 | +53.19% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $1.28 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $4.49 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $2.40 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $3.55 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $6.55 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.15 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.33 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.11 | +1,084.83% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $140.14 | +235.38% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.10 | +509.76% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20,000 → $17,500 | $0.51 | +3,431,272.55% | 5 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $52.91 | +174.05% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $57.07
Upside: +26.16%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $26.01
Upside: -3.88%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $32.65
Upside: +62.33%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $78.97
Upside: +20.30%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $11.75
Upside: +53.19%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.28
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.49
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.40
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.55
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.55
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.15
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.33
Upside: -
May 11, 2021
Initiates: Buy
Price Target: $25
Current: $2.11
Upside: +1,084.83%
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $140.14
Upside: +235.38%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $4.10
Upside: +509.76%
Nov 5, 2020
Maintains: Buy
Price Target: $20,000 → $17,500
Current: $0.51
Upside: +3,431,272.55%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $52.91
Upside: +174.05%